Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (16 ops.)
Latest filing published 20 Oct 2026 for Roivant Sciences Ltd., €1.0M.
Filing timeline
BuySaleMatthew Gline
Insider track record
Disclosed buys
1
Disclosed sells
16
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +122.9%Entry US$15.04 · Close 16 Oct 2026 US$33.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthew Gline: trading record in brief
The largest sale of Matthew Gline, CEO of Roivant Sciences Ltd., the only company in the record, is EUR 21,043,172, on September 23, 2024; two others, EUR 17,427,409 and EUR 10,456,442, fall on the same day, December 15, 2025. In all, 16 open-market sales are worth EUR 62,422,755, with a median of EUR 270,826.
The single purchase is EUR 42,369, on September 18, 2025, which is 6% of market trades. The 76 filings, published from March 9, 2022 to October 20, 2026, also include 28 share grants, 20 other lines and 11 option exercises.
The yearly peak is 22 filings in 2023, against 14 in 2022, 19 in 2024, 15 in 2025 and 6 in 2026. Fifteen filings fall in the last twelve months, with 4 sales and no purchase.
At Roivant, 17 of Gline's market trades fall within 30 days of a trade by Eric Venker (16 in the same direction) and 12 of a trade by Rakhi Kumar, in the same direction. Daniel Allen Gold, Keith S. Manchester and QVT Financial LP have 5 each, also in the same direction.
Companies and markets linked to Matthew Gline
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations76 total
34,638 shares@ US$33.530.0046% mcap4.0% of flowCommon SharesSEC:0001635088-26-000113:0
76,171 shares@ US$36.570.011% mcap9.9% of flowCommon SharesSEC:0001140361-26-038475:0
289,774 shares@ US$29.160.032% mcap32.2% of flowCommon SharesSEC:0001635088-26-000038:0
53,826 shares@ US$26.415.6% of flowCommon SharesSEC:0001635088-26-000034:1
304,684 shares@ US$27.7032.7% of flowCommon SharesSEC:0001635088-26-000034:2
97,319 sharesCommon SharesSEC:0001635088-26-000034:0
797,595 shares@ US$21.688.6% of flowCommon SharesSEC:0001140361-25-045906:5
230,357 shares@ US$21.682.5% of flowCommon SharesSEC:0001140361-25-045906:1
3,739 shares@ US$21.680.0% of flowCommon SharesSEC:0001140361-25-045906:2
1,363,711 shares@ US$12.688.6% of flowCommon SharesSEC:0001140361-25-045906:3
566,116 shares@ US$21.686.1% of flowCommon SharesSEC:0001140361-25-045906:4
2,272,852 shares@ US$12.6814.3% of flowCommon SharesSEC:0001140361-25-045906:6
943,527 shares@ US$21.6810.2% of flowCommon SharesSEC:0001140361-25-045906:7
1,329,325 shares@ US$21.6814.3% of flowCommon SharesSEC:0001140361-25-045906:8
234,096 shares@ US$4.063.6% of flowCommon SharesSEC:0001140361-25-045906:0
3,315 shares@ US$15.070.2% of flowCommon SharesSEC:0001140361-25-035435:0
Canonical exit: 17 Dec 2025 (T+90)
10,945 shares@ US$11.040.5% of flowCommon SharesSEC:0001140361-25-020240:0
10,945 shares@ US$10.150.4% of flowCommon SharesSEC:0001140361-25-014985:0
10,945 shares@ US$10.970.5% of flowCommon SharesSEC:0001140361-25-010117:0
10,945 shares@ US$10.720.5% of flowCommon SharesSEC:0001140361-25-005718:0
11,623 shares@ US$11.150.6% of flowCommon SharesSEC:0001140361-25-001661:0
10,945 shares@ US$11.570.5% of flowCommon SharesSEC:0001140361-24-050457:0
10,945 shares@ US$11.490.5% of flowCommon SharesSEC:0001140361-24-047696:0
10,945 shares@ US$11.920.5% of flowCommon SharesSEC:0001140361-24-043960:0
1,550,000 shares@ US$3.853.1% of flowCommon SharesSEC:0001140361-24-041788:1
25 of 76 declarations
